COVID-19 Pfizer Information
Covid-19 Pfizer Information
A Once-weekly Treatment for Hemophilia B
Pfizer's Sponsored Scientific Presentations including Abstract Plain Language Summaries
The Role of Cyclin-Dependent Kinases (CDK) 2/4/6 in Normal and Tumor Cells
Exploring Alternative Targets in Hemophilia- Revisiting Tissue Factor Pathway Inhibitor
Pfizer Gene Therapy
Pfizer’s Leadership Through Science: Driving Innovation in Hematology PDF Invite
Medical Information
Clinical Trial Resources
Global Medical Grants Oncology Brochure
Hard-to-Reach ABC/mBC Communities Toolkit
Pfizer Oncology Collaborating to Improve Patient Centricity in Clinical Trials
Perspectives by Colleagues Video
What to Expect With Your Cancer Care During COVID-19
What to Expect With Your Cancer Care During COVID-19 – Spanish Version
Pfizer Oncology Patient Centricity Ecosystem: From Launch to Impact
This Is Living With Cancer
Pfizer Oncology Together
Hemophilia Patient Support Brochure
Hemophilia Village
Benefix Prescribing Information
Benefix Product Summary
Benefix Product Website
Xyntha Solofuse® Prescribing Information
Xyntha Solofuse® Product Summary
Xyntha Solofuse® Product Website
Hemophilia Support
Abstract Plain Language Summaries
Hematologic Malignancies
Find My U.S. Field Medical Director
Follow US
Investigator Information and How to Contact Us
Digitally Empowered (a collaboration between Patient Empowerment Network and Pfizer)
African American Men’s Health Checklist
Age: Addressing a Blind Spot in Cancer Care
Some Older People Living with Cancer Aim for Remission but Lack Needed Resources to Help Make Treatment Decisions
BCMA Bispecific Clinical Trials MagnetisMM-3 Clinical Trial
BCMA Bispecific Clinical Trials MagnetisMM-9 Clinical Trial
Learn About Our Hematology Approved Medicines
Pfizer’s Leadership Through Science: Driving Innovation in Hematology Add To Calendar
A Treatment Option for Adult Patients With Newly Diagnosed CP Ph+ CML or Patients With CML Resistant/Intolerant to Prior TKI Therapy PDF Invite
A Treatment Option for Adult Patients With Newly Diagnosed CP Ph+ CML or Patients With CML Resistant/Intolerant to Prior TKI Therapy Add To Calendar
Pfizer Rare Disease Pipeline
Independent Medical Education Grant: Multidisciplinary Gene Therapy Education - Recombinant Adeno-Associated Virus
Global Hemophilia ASPIRE Grant
Pfizer Hemophilia Presentations and Abstracts
Where Could Hemophilia Treatment Be Going Next?
Hematologic Malignancies Narrative
Digital Briefcase
"Be A BsAb in MM" Photo Activity
Pfizer Oncology Development Program
Welcome to our innovative virtual congress portal, which incorporates both our Malignant and Benign Hematology portfolios in one virtual exhibit experience. We hope you find this a valuable resource where you can access information on Pfizer’s scientific presence at this year’s meeting as well as background on our malignant and benign hematology development programs and approved medicines. As leaders in Hematology, we are excited to come together in this forum to advance scientific research for people living with benign and malignant hematologic conditions and hope you will make the most of this resource.
The ASH annual meeting is a cornerstone for hematology research and an opportunity to get updated on the evolving landscape and management of hematologic conditions, and this year we are adapting our ASH presence and engagement activities as a result of COVID-19 pandemic and to align with the hybrid approach to allow for dual experiences. If you would like more information on how Pfizer is responding to this pandemic, we would encourage you to click here.
We thank you for the important work you do every day on behalf of people living with benign and malignant hematologic conditions. We hope you have a successful meeting.
Opportunities To Connect
Connect with Pfizer
through our Contact Form
Find My U.S.
Field Medical Director
A team member will respond to your inquiry.
Add To Calendar
Oral Presentations
Poster Presentations
Product Theater
Industry Theater
Learn About Our Hemophilia A and B Approved Products
Learn About Our Hematology Approved Medicines
PF-06863135 is an investigational compound and has not been approved by any Regulatory Authority as safe or effective for any use. The preclinical and in vitro evidence presented here may not necessarily correlate with clinical outcomes.
